NeoChord Nexus TMVR Device Successfully Used in First-In-Human Procedure

October 4, 2021—NeoChord, Inc. announced the successful completion of the first-in-human procedure with the NeoChord Nexus transcatheter mitral chordal repair (TMVR) technology. The procedure was performed at the University Hospital of Bordeaux, France in collaboration with the Universitätsmedizin Mainz, Germany. The patient treated has been discharged from the hospital and is back to a normal lifestyle.

The procedure was led by Thomas Modine, MD, of the University Hospital of Bordeaux and Ralph Stephan von Bardeleben, MD, of the Universitätsmedizin Mainz. Dr. Modine and Dr. von Bardeleben commented in the company’s press release, “We are pleased with the positive result of this first-in-human procedure of the NeoChord Nexus transcatheter mitral chordal repair device. The ability to replace a ruptured native chord by precisely placing suture in the mitral leaflet and securing with an anchor contributed to a very safe procedure. We integrated four decades of heart surgical experience into a venous transseptal intervention.”

Azeem Latib, MD, who is closely involved in the development of the NeoChord Nexus TMVR device and procedure, stated in the announcement, “Chordal replacement was completed in textbook fashion. Minimally invasive transcatheter chordal repair offers the promise of driving surgical-like results by maintaining the physiologic construction of the mitral valve, translating to better long-term outcomes.” Dr. Latib is with the Division of Cardiology at Montefiore Medical Center and Albert Einstein College of Medicine in New York, New York.

According to the company, the investigational NeoChord Nexus device is designed to restore function in patients with severe symptomatic primary mitral regurgitation while maintaining the natural physiologic functionality of the mitral valve. It is deployed with a transfemoral delivery catheter and navigated transeptally to the diseased native mitral valve. Because of the minimal hardware used and the proven leaflet connection, NeoChord Nexus preserves options for patients who may need re-intervention in the future, stated the company.

NeoChord is a privately held medical technology company. The company’s commercially available product, the NeoChord artificial chordae delivery system DS1000, received CE Mark approval in December 2012. The NeoChord Nexus is an investigational device and not commercially available, advised the company.